Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RPTX Repare Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: RPTX
Price (delayed)
$1.34
Market cap
$57.47M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.02
Enterprise value
-$25.61M
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled
Highlights
RPTX's debt has dropped by 51% year-on-year and by 29% since the previous quarter
RPTX's quick ratio is down by 15% year-on-year but it is up by 9% since the previous quarter
RPTX's net income has dropped by 180% year-on-year and by 51% since the previous quarter
RPTX's EPS has plunged by 177% YoY and by 51% from the previous quarter
Key stats
What are the main financial stats of RPTX
Market
Valuations
Earnings
Shares outstanding
42.89M
Market cap
$57.47M
Enterprise value
-$25.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.46
Price to sales (P/S)
53.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-23.87
Revenue
$1.07M
Gross profit
$1.07M
Operating income
-$135.53M
Net income
-$127.89M
EBIT
-$126.71M
EBITDA
-$121.75M
Free cash flow
-$117.51M
Per share
Balance sheet
Liquidity
EPS
-$3.02
EPS diluted
-$3.02
Free cash flow per share
-$2.76
Book value per share
$2.94
Revenue per share
$0.03
TBVPS
$3.38
Total assets
$144.02M
Total liabilities
$18.93M
Debt
$1.37M
Equity
$125.1M
Working capital
$121.42M
Debt to equity
0.01
Current ratio
7.42
Quick ratio
6.65
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
-11,346.9%
Gross margin
100%
Net margin
-11,919.3%
Operating margin
-12,630.6%
Return on assets
-67.1%
Return on equity
-78.1%
Return on invested capital
-151.7%
Return on capital employed
-101.3%
Return on sales
-11,809.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RPTX stock price
How has the Repare Therapeutics stock price performed over time
Intraday
0.75%
1 week
-1.47%
1 month
16.52%
1 year
-62.04%
YTD
2.29%
QTD
35.92%
Financial performance
How have Repare Therapeutics's revenue and profit performed over time
Revenue
$1.07M
Gross profit
$1.07M
Operating income
-$135.53M
Net income
-$127.89M
Gross margin
100%
Net margin
-11,919.3%
RPTX's net income has dropped by 180% year-on-year and by 51% since the previous quarter
Repare Therapeutics's gross profit has plunged by 99% YoY and by 98% from the previous quarter
Repare Therapeutics's revenue has plunged by 99% YoY and by 98% from the previous quarter
RPTX's operating income has shrunk by 92% YoY and by 45% QoQ
Price vs fundamentals
How does RPTX's price correlate with its fundamentals
Growth
What is Repare Therapeutics's growth rate over time
Valuation
What is Repare Therapeutics stock price valuation
P/E
N/A
P/B
0.46
P/S
53.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-23.87
RPTX's EPS has plunged by 177% YoY and by 51% from the previous quarter
The P/B is 80% below the 5-year quarterly average of 2.3 and 23% below the last 4 quarters average of 0.6
The equity has contracted by 46% YoY and by 17% from the previous quarter
Repare Therapeutics's revenue has plunged by 99% YoY and by 98% from the previous quarter
The P/S is 92% lower than the 5-year quarterly average of 684.0
Efficiency
How efficient is Repare Therapeutics business performance
Repare Therapeutics's ROIC has plunged by 93% from the previous quarter
RPTX's return on equity has dropped by 76% since the previous quarter
The ROA has plunged by 75% from the previous quarter
Dividends
What is RPTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RPTX.
Financial health
How did Repare Therapeutics financials performed over time
The company's total assets fell by 45% YoY and by 18% QoQ
Repare Therapeutics's total liabilities has decreased by 39% YoY and by 25% QoQ
RPTX's debt is 99% smaller than its equity
RPTX's debt has dropped by 51% year-on-year and by 29% since the previous quarter
The equity has contracted by 46% YoY and by 17% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.